Annual SG&A
$5.94 M
-$673.00 K-10.17%
31 December 2023
Summary:
Galectin Therapeutics annual selling, general & administrative expenses is currently $5.94 million, with the most recent change of -$673.00 thousand (-10.17%) on 31 December 2023. During the last 3 years, it has risen by +$474.00 thousand (+8.67%). GALT annual SG&A is now -16.67% below its all-time high of $7.13 million, reached on 31 December 2018.GALT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.47 M
-$7000.00-0.47%
30 September 2024
Summary:
Galectin Therapeutics quarterly selling, general & administrative expenses is currently $1.47 million, with the most recent change of -$7000.00 (-0.47%) on 30 September 2024. Over the past year, it has increased by +$37.00 thousand (+2.58%). GALT quarterly SG&A is now -41.39% below its all-time high of $2.51 million, reached on 31 December 2011.GALT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.49 B
-$45.23 M-3.13%
30 September 2024
Summary:
Galectin Therapeutics TTM selling, general & administrative expenses is currently -$1.49 billion, with the most recent change of -$45.23 million (-3.13%) on 30 September 2024. Over the past year, it has dropped by -$1.49 billion (-23966.67%). GALT TTM SG&A is now -158106.15% below its all-time high of $7.70 million, reached on 31 March 2016.GALT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.2% | +2.6% | -10000.0% |
| 3 y3 years | +8.7% | -9.8% | -10000.0% |
| 5 y5 years | -16.7% | +8.2% | -10000.0% |
GALT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -10.2% | +8.7% | -21.6% | +10.3% | -48.1% | at low |
| 5 y | 5 years | -16.7% | +8.7% | -21.6% | +28.4% | -81.2% | at low |
| alltime | all time | -16.7% | +361.1% | -41.4% | +430.1% | <-9999.0% | at low |
Galectin Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.47 M(-0.5%) | $5.88 M(+0.6%) |
| June 2024 | - | $1.48 M(-7.3%) | $5.84 M(-2.6%) |
| Mar 2024 | - | $1.59 M(+19.6%) | $5.99 M(+0.9%) |
| Dec 2023 | $5.94 M(-10.2%) | $1.33 M(-7.0%) | $5.94 M(-4.7%) |
| Sept 2023 | - | $1.43 M(-12.1%) | $6.24 M(-1.4%) |
| June 2023 | - | $1.63 M(+5.8%) | $6.33 M(+0.7%) |
| Mar 2023 | - | $1.54 M(-5.1%) | $6.28 M(-5.0%) |
| Dec 2022 | $6.62 M(+4.0%) | $1.63 M(+6.7%) | $6.62 M(+0.9%) |
| Sept 2022 | - | $1.52 M(-4.0%) | $6.56 M(-1.6%) |
| June 2022 | - | $1.59 M(-15.4%) | $6.67 M(-2.3%) |
| Mar 2022 | - | $1.88 M(+19.6%) | $6.82 M(+7.2%) |
| Dec 2021 | $6.36 M(+16.3%) | $1.57 M(-3.8%) | $6.36 M(+1.7%) |
| Sept 2021 | - | $1.63 M(-6.4%) | $6.25 M(+8.4%) |
| June 2021 | - | $1.74 M(+22.9%) | $5.77 M(+5.9%) |
| Mar 2021 | - | $1.42 M(-2.9%) | $5.45 M(-0.4%) |
| Dec 2020 | $5.47 M(-8.4%) | $1.46 M(+27.5%) | $5.47 M(+1.3%) |
| Sept 2020 | - | $1.15 M(-19.4%) | $5.40 M(-3.8%) |
| June 2020 | - | $1.42 M(-1.3%) | $5.61 M(-1.4%) |
| Mar 2020 | - | $1.44 M(+3.4%) | $5.69 M(-4.7%) |
| Dec 2019 | $5.97 M(-16.3%) | $1.39 M(+2.4%) | $5.97 M(-6.3%) |
| Sept 2019 | - | $1.36 M(-9.2%) | $6.37 M(+3.0%) |
| June 2019 | - | $1.50 M(-13.0%) | $6.19 M(-11.3%) |
| Mar 2019 | - | $1.72 M(-4.0%) | $6.97 M(-2.2%) |
| Dec 2018 | $7.13 M(+57.6%) | $1.79 M(+52.6%) | $7.13 M(+6.3%) |
| Sept 2018 | - | $1.18 M(-48.5%) | $6.71 M(+4.1%) |
| June 2018 | - | $2.28 M(+21.4%) | $6.45 M(+23.2%) |
| Mar 2018 | - | $1.88 M(+37.1%) | $5.23 M(+15.6%) |
| Dec 2017 | $4.53 M(-26.5%) | $1.37 M(+50.5%) | $4.53 M(+4.7%) |
| Sept 2017 | - | $911.00 K(-14.9%) | $4.32 M(-7.2%) |
| June 2017 | - | $1.07 M(-8.9%) | $4.66 M(-4.8%) |
| Mar 2017 | - | $1.17 M(+0.7%) | $4.89 M(-20.5%) |
| Dec 2016 | $6.16 M(-11.6%) | $1.17 M(-6.6%) | $6.16 M(-8.9%) |
| Sept 2016 | - | $1.25 M(-4.4%) | $6.76 M(-2.7%) |
| June 2016 | - | $1.30 M(-46.5%) | $6.95 M(-9.8%) |
| Mar 2016 | - | $2.44 M(+37.8%) | $7.70 M(+10.5%) |
| Dec 2015 | $6.96 M(-0.6%) | $1.77 M(+23.3%) | $6.96 M(+1.7%) |
| Sept 2015 | - | $1.44 M(-30.2%) | $6.85 M(-0.9%) |
| June 2015 | - | $2.06 M(+20.7%) | $6.91 M(+4.2%) |
| Mar 2015 | - | $1.70 M(+3.0%) | $6.64 M(-5.3%) |
| Dec 2014 | $7.00 M(+9.2%) | $1.65 M(+10.4%) | $7.00 M(+3.6%) |
| Sept 2014 | - | $1.50 M(-15.9%) | $6.76 M(-11.2%) |
| June 2014 | - | $1.78 M(-14.0%) | $7.62 M(+8.3%) |
| Mar 2014 | - | $2.07 M(+47.1%) | $7.03 M(+9.6%) |
| Dec 2013 | $6.42 M(+19.4%) | $1.41 M(-40.1%) | $6.42 M(+0.5%) |
| Sept 2013 | - | $2.35 M(+96.4%) | $6.39 M(+15.7%) |
| June 2013 | - | $1.20 M(-17.7%) | $5.52 M(-4.4%) |
| Mar 2013 | - | $1.46 M(+5.5%) | $5.78 M(+7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | $5.37 M(-21.7%) | $1.38 M(-7.2%) | $5.37 M(-17.4%) |
| Sept 2012 | - | $1.49 M(+2.3%) | $6.50 M(+1.7%) |
| June 2012 | - | $1.45 M(+38.1%) | $6.39 M(-3.7%) |
| Mar 2012 | - | $1.05 M(-58.1%) | $6.64 M(-3.2%) |
| Dec 2011 | $6.86 M(+79.6%) | $2.51 M(+82.1%) | $6.86 M(+30.7%) |
| Sept 2011 | - | $1.38 M(-18.9%) | $5.25 M(+10.0%) |
| June 2011 | - | $1.70 M(+34.0%) | $4.77 M(+14.0%) |
| Mar 2011 | - | $1.27 M(+41.2%) | $4.18 M(+9.6%) |
| Dec 2010 | $3.82 M(-23.4%) | $899.00 K(0.0%) | $3.82 M(+0.7%) |
| Sept 2010 | - | $899.00 K(-19.4%) | $3.79 M(-1.6%) |
| June 2010 | - | $1.12 M(+23.6%) | $3.85 M(-10.5%) |
| Mar 2010 | - | $903.00 K(+3.6%) | $4.30 M(-13.6%) |
| Dec 2009 | $4.98 M(+40.3%) | $872.00 K(-9.3%) | $4.98 M(+0.8%) |
| Sept 2009 | - | $961.00 K(-38.8%) | $4.94 M(+7.9%) |
| June 2009 | - | $1.57 M(-0.8%) | $4.58 M(+10.6%) |
| Mar 2009 | - | $1.58 M(+90.3%) | $4.14 M(+16.6%) |
| Dec 2008 | $3.55 M(-19.3%) | $831.00 K(+38.3%) | $3.55 M(-4.7%) |
| Sept 2008 | - | $601.00 K(-46.8%) | $3.73 M(-10.5%) |
| June 2008 | - | $1.13 M(+14.1%) | $4.16 M(+0.6%) |
| Mar 2008 | - | $990.00 K(-1.6%) | $4.14 M(-6.0%) |
| Dec 2007 | $4.40 M(+9.3%) | $1.01 M(-2.9%) | $4.40 M(+10.4%) |
| Sept 2007 | - | $1.04 M(-6.2%) | $3.99 M(-0.7%) |
| June 2007 | - | $1.10 M(-12.1%) | $4.02 M(+0.1%) |
| Mar 2007 | - | $1.26 M(+112.2%) | $4.01 M(-0.3%) |
| Dec 2006 | $4.03 M(+11.5%) | $592.00 K(-44.5%) | $4.03 M(-9.6%) |
| Sept 2006 | - | $1.07 M(-3.2%) | $4.46 M(+5.2%) |
| June 2006 | - | $1.10 M(-13.3%) | $4.24 M(+5.1%) |
| Mar 2006 | - | $1.27 M(+24.4%) | $4.03 M(+11.6%) |
| Dec 2005 | $3.62 M(-15.2%) | $1.02 M(+20.7%) | $3.62 M(-4.5%) |
| Sept 2005 | - | $846.00 K(-5.7%) | $3.79 M(-7.0%) |
| June 2005 | - | $897.00 K(+5.3%) | $4.07 M(-0.4%) |
| Mar 2005 | - | $852.00 K(-28.5%) | $4.09 M(-4.0%) |
| Dec 2004 | $4.26 M(+42.6%) | $1.19 M(+5.2%) | $4.26 M(+7.1%) |
| Sept 2004 | - | $1.13 M(+23.8%) | $3.98 M(+4.9%) |
| June 2004 | - | $915.00 K(-10.5%) | $3.79 M(+9.9%) |
| Mar 2004 | - | $1.02 M(+12.4%) | $3.45 M(+15.5%) |
| Dec 2003 | $2.99 M(+65.6%) | $909.30 K(-3.8%) | $2.99 M(+8.2%) |
| Sept 2003 | - | $945.60 K(+64.8%) | $2.76 M(+29.1%) |
| June 2003 | - | $573.90 K(+2.6%) | $2.14 M(+9.4%) |
| Mar 2003 | - | $559.20 K(-18.2%) | $1.96 M(+8.4%) |
| Dec 2002 | $1.80 M(+40.0%) | $683.80 K(+112.1%) | $1.80 M(+18.3%) |
| Sept 2002 | - | $322.40 K(-17.3%) | $1.52 M(+3.0%) |
| June 2002 | - | $389.90 K(-4.5%) | $1.48 M(-4.5%) |
| Mar 2002 | - | $408.10 K(+0.9%) | $1.55 M(+35.8%) |
| Dec 2001 | $1.29 M | $404.50 K(+45.8%) | $1.14 M(+54.9%) |
| Sept 2001 | - | $277.50 K(-39.6%) | $736.80 K(+60.4%) |
| June 2001 | - | $459.30 K | $459.30 K |
FAQ
- What is Galectin Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Galectin Therapeutics?
- What is Galectin Therapeutics annual SG&A year-on-year change?
- What is Galectin Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly SG&A year-on-year change?
- What is Galectin Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Galectin Therapeutics?
- What is Galectin Therapeutics TTM SG&A year-on-year change?
What is Galectin Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of GALT is $5.94 M
What is the all time high annual SG&A for Galectin Therapeutics?
Galectin Therapeutics all-time high annual selling, general & administrative expenses is $7.13 M
What is Galectin Therapeutics annual SG&A year-on-year change?
Over the past year, GALT annual selling, general & administrative expenses has changed by -$673.00 K (-10.17%)
What is Galectin Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of GALT is $1.47 M
What is the all time high quarterly SG&A for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly selling, general & administrative expenses is $2.51 M
What is Galectin Therapeutics quarterly SG&A year-on-year change?
Over the past year, GALT quarterly selling, general & administrative expenses has changed by +$37.00 K (+2.58%)
What is Galectin Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of GALT is -$1.49 B
What is the all time high TTM SG&A for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM selling, general & administrative expenses is $7.70 M
What is Galectin Therapeutics TTM SG&A year-on-year change?
Over the past year, GALT TTM selling, general & administrative expenses has changed by -$1.49 B (-23966.67%)